title: Trends in early aspirin use among patients with acute myocardial infarction in China, 2001-2011: the China PEACE-Retrospective AMI study.
abstract: BACKGROUND
  Aspirin is an effective, safe, and inexpensive early treatment of acute myocardial infarction (AMI) with few barriers to administration, even in countries with limited healthcare resources. However, the rates and recent trends of aspirin use for the early treatment of AMI in China are unknown.
  
  
  RESULTS
  Using data from the China Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction (China PEACE-Retrospective AMI Study), we identified a cohort of 14 041 patients with AMI eligible for early aspirin therapy. Early use of aspirin for AMI increased over time (78.4% in 2001, 86.5% in 2006, and 90.0% in 2011). However, about 15% of hospitals had a rate of use of <80% in 2011. Treatment was less likely in patients who were older, presented with cardiogenic shock at admission, presented without chest discomfort, had a final diagnosis of non-ST-segment elevation acute myocardial infarction, or did not receive reperfusion therapy. Hospitalization in rural regions was also associated with aspirin underuse.
  
  
  CONCLUSIONS
  Despite improvements in early use of aspirin for AMI in China, there remains marked variation in practice and opportunities for improvement that are concentrated in some hospitals and patient groups.
  
  
  BACKGROUND
  ClinicalTrials.gov Unique identifier: NCT01624883.
authors.affiliation: National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.G., S.H., J.L., H.Z., X.L., L.J.).
authors.forename: Yan
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora, CO (F.A.M.).
authors.forename: Frederick A
authors.initials: FA
authors.lastname: Masoudi
authors.affiliation: National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.G., S.H., J.L., H.Z., X.L., L.J.).
authors.forename: Shuang
authors.initials: S
authors.lastname: Hu
authors.affiliation: National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.G., S.H., J.L., H.Z., X.L., L.J.).
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.G., S.H., J.L., H.Z., X.L., L.J.).
authors.forename: Haibo
authors.initials: H
authors.lastname: Zhang
authors.affiliation: National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.G., S.H., J.L., H.Z., X.L., L.J.).
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.affiliation: Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (N.R.D., H.M.K.).
authors.forename: Nihar R
authors.initials: NR
authors.lastname: Desai
authors.affiliation: Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (N.R.D., H.M.K.).
authors.forename: Harlan M
authors.initials: HM
authors.lastname: Krumholz
authors.affiliation: National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Y.G., S.H., J.L., H.Z., X.L., L.J.).
authors.forename: Lixin
authors.initials: L
authors.lastname: Jiang
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002681:China; D015331:Cohort Studies; D016001:Confidence Intervals; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D016017:Odds Ratio; D012189:Retrospective Studies; D018570:Risk Assessment; D012424:Rural Population; D055502:Secondary Prevention / Q000379:methods*; D012737:Sex Factors; D016019:Survival Analysis; D015996:Survival Rate; D014505:Urban Population
chemical_list: D001241:Aspirin
keywords: acute myocardial infarction; aspirin; quality of care